Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NICE recommends against Orencia on NHS
The National Institute for Clinical Excellence and Health, or NICE, said in the draft recommendation that Biogen Idec’s MabThera (rituximab) had very similar outcomes to Orencia (abatacept) at
The National Institute for Clinical Excellence and Health, or NICE, said in the draft recommendation that Biogen Idec’s MabThera (rituximab) had very similar outcomes to Orencia (abatacept) at
The company said that while it regrets Bisaro’s decision to leave, it is confident that the departure will not have a negative effect on US or international operations
As a result of the reduction in workforce, effective August 3, 2007, the company expects to have less than 80 employees, a reduction of 45% from year end
Johnson & Johnson (J&J) has revealed initiatives that are expected to generate pre-tax, annual cost savings of between $1.3 and $1.6 billion for 2008, in an effort to
The company said that it is halting further development of ANA380, a nucleotide analog for the treatment of hepatitis B virus infection, with all rights to this compound
Termination of the agreement will be effective 90 days from August 22, 2007. As a result, MethylGene will regain exclusive rights to its beta-lactamase inhibitor program to overcome
The studies of PEG-SN38, Enzon’s pegylated form of SN38, the active metabolite of the cancer drug Camptosar, are designed to evaluate the safety, tolerability, and pharmacokinetics of the
In the studies, 30% of StatC-treated lung samples had H5N1 virus detected in comparison to 50% of Tamiflu treated samples, according to the company. Histopathology which measures lung
The placebo-controlled, dose-escalation study is designed to evaluate the safety and tolerability of multiple doses of the antibody. This trial is the second phase IIa study currently underway
Orphan drug status is granted to drug candidates that are developed for severe, disabling diseases for which there are currently no satisfactory products on the market. Moreover, a